NO943540L - Antiviral peptides - Google Patents

Antiviral peptides

Info

Publication number
NO943540L
NO943540L NO943540A NO943540A NO943540L NO 943540 L NO943540 L NO 943540L NO 943540 A NO943540 A NO 943540A NO 943540 A NO943540 A NO 943540A NO 943540 L NO943540 L NO 943540L
Authority
NO
Norway
Prior art keywords
alkyl
cycloalkyl
aryl
group
heterocyclyl
Prior art date
Application number
NO943540A
Other languages
Norwegian (no)
Other versions
NO943540D0 (en
Inventor
Colin William Greengrass
Stephen Derek Albert Street
Peter John Whittle
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929206462A external-priority patent/GB9206462D0/en
Priority claimed from GB939301638A external-priority patent/GB9301638D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of NO943540D0 publication Critical patent/NO943540D0/en
Publication of NO943540L publication Critical patent/NO943540L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Forbindelse av formel (I) o R2 R4 HO R3 o og farmasøytisk akseptable salter derav og bioprekursorer for dette, hvor R1 er 0,-C^alkyl, C3-C8-cykloalkyl, aryl, heterocyklyl eller CONR9R10; R2 er C^Cg-alkyl, C3-C8-cykloalkyl-(C1-C4)-alkyl, aryl- (C^-C^-alkyl eller heterocyklyl-^-C^-alkyl; R3 er C^Cg-alkyl, C3-C8-cykloalkyl, Cg-Ca-cykloalkyl-^-C^-alkyl, aryl-^-C^alkyl, aryl-CCg-C^-alkenyl, heterocyklyHC^-C^-alkyl eller heterocyklyl- (Cj-C^-alkenyl; R4 er 0,-Cg-alkyl, C3-C8-cykloalkyl, aryl eller heterocyklyl; hver av R5, R6, R7 og R8 er uavhengig av hverandre H, C1-C6-alkyl eller C3-C8-cykloalkyl, eller R5 og R6 eller R7 og R8 kan bli slått sammen for å danne en 3- til 8-leddet karbocyklisk ring; X er en 4- til 10-leddet mono- eller bicyklisk heterocyklisk gruppe inne- holdende karbonringatomer og ett ringnitrogenatom via hvilket gruppen er bundet til den hosliggende karbonylgruppe; gruppen kan være mettet eller delvis umettet og i tillegg til -(CR7R8)m-Het-substituenten kan den være substituert med opp til fire ytterligere substituenter, uavhengig valgt fra F, C^Cg-alkyl, C3-C8-cykloalkyl, OR11 eller NR9R10; Het er en imidazolyl- eller triazolylgruppe hvorav hver even- tuelt kan være substituert med C1-C6-alkyl, C3-C7-cykloalkyl, NR9R10 eller CONR9R10; hvor hver av R9 og R10 uavhengig av hverandre er H, C^-Ce-alkyl eller C3-C8-cykloalkyl eller R9 og R10 kan bli slått sammen for å danne, med nitrogenet til hvilket de er bundet, en 4- til 8-leddet nitrogeninneholdende heterocyklisk gruppe; R11 er H, C^-Cg-alkyl eller C3-C8-cykloalkyl; n og m er hver uavhengig av hverandre O, 1 eller 2, hvor enhver alkyl- eller cykloalkylgruppe Inkludert l ovenfor nevnte definisjoner eventuelt kan være fullstendig eller delvis substituert med fluor; er inhibitorer for retrovirale proteaser med anvendelighet for behandling og profylakse av humane retrovirale infeksjoner.Compound of Formula (I) o R 2 R 4 HO R 3 o and pharmaceutically acceptable salts thereof and bioprecursors thereof, wherein R 1 is O, -C 1-6 alkyl, C 3 -C 8 cycloalkyl, aryl, heterocyclyl or CONR9R10; R 2 is C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl (C 1 -C 4) alkyl, aryl- (C 1 -C 4 alkyl or heterocyclyl - 1 -C 3 -alkyl; R 3 is C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, C 9 -C 8 cycloalkyl - C 1 -C 4 alkyl, aryl - C 1 -C 4 alkyl, aryl-C 6 -C 3 -alkenyl, heterocyclyHC 1 -C 3 alkyl or heterocyclyl- (C R 4 is O, -C 8 alkyl, C 3 -C 8 cycloalkyl, aryl or heterocyclyl; each of R 5, R 6, R 7 and R 8 is independently H, C 1 -C 6 alkyl or C 3 -C 8 cycloalkyl, or R5 and R6 or R7 and R8 may be combined to form a 3- to 8-membered carbocyclic ring; X is a 4- to 10-membered mono- or bicyclic heterocyclic group containing carbon ring atoms and one ring nitrogen atom through which the group is bonded to the adjacent carbonyl group; the group may be saturated or partially unsaturated and in addition to the - (CR7R8) m-Het substituent it may be substituted with up to four additional substituents independently selected from F, C -C8-cycloalkyl, OR11 or NR9R10; Het is an imidazolyl or triazolyl group of which each may be optionally substituted with C1-C6 alkyl, C3-C7 cycloalkyl, NR9R10 or CONR9R10; wherein each of R9 and R10 are independently H, C1-C6 alkyl or C3-C8 cycloalkyl or R9 and R10 may be combined to form, with the nitrogen to which they are attached, a 4- to 8- linked nitrogen-containing heterocyclic group; R 11 is H, C 1 -C 8 alkyl or C 3 -C 8 cycloalkyl; n and m are each independently 0, 1 or 2, wherein any alkyl or cycloalkyl group Included in the above-mentioned definitions may optionally be fully or partially substituted with fluorine; are inhibitors of retroviral proteases with utility for the treatment and prophylaxis of human retroviral infections.

NO943540A 1992-03-25 1994-09-23 Antiviral peptides NO943540L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB929206462A GB9206462D0 (en) 1992-03-25 1992-03-25 Antiviral peptides
GB939301638A GB9301638D0 (en) 1993-01-27 1993-01-27 Antiviral peptides
PCT/EP1993/000597 WO1993019059A1 (en) 1992-03-25 1993-03-13 Antiviral peptides

Publications (2)

Publication Number Publication Date
NO943540D0 NO943540D0 (en) 1994-09-23
NO943540L true NO943540L (en) 1994-11-21

Family

ID=26300586

Family Applications (1)

Application Number Title Priority Date Filing Date
NO943540A NO943540L (en) 1992-03-25 1994-09-23 Antiviral peptides

Country Status (13)

Country Link
EP (1) EP0632808A1 (en)
JP (1) JPH07501556A (en)
KR (1) KR950700901A (en)
AU (1) AU3748393A (en)
BR (1) BR9306138A (en)
CA (1) CA2131154A1 (en)
CZ (1) CZ229594A3 (en)
FI (1) FI944428A0 (en)
HU (1) HU9402744D0 (en)
NO (1) NO943540L (en)
RU (1) RU94041225A (en)
SK (1) SK114094A3 (en)
WO (1) WO1993019059A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2094344T3 (en) * 1991-01-02 1997-01-16 Merrell Pharma Inc ANTI-VIRAL COMPOUNDS.
CA2166693C (en) * 1993-07-08 1999-08-24 Daniel Schirlin Difluoro statone analogs
CN1130898A (en) * 1993-09-09 1996-09-11 默里尔药物公司 Difluoro statone antiviral analogs
US6114380A (en) * 1995-12-18 2000-09-05 Merrell Pharmaceuticals Inc. Difluoro statone analogs
GB9601680D0 (en) 1996-01-27 1996-03-27 Pfizer Ltd Therapeutic agents
PT1058683E (en) * 1998-02-02 2003-04-30 Lg Chemical Ltd FARNESIL-TRANSFERASE INHIBITORS WITH A PIPERIDINE STRUCTURE AND PREPARATION PROCESS
US6809200B2 (en) 2000-07-28 2004-10-26 Pfizer Inc. Process for the preparation of pyrazolo[4,3-d]pyrimidin-7-one compounds and intermediates thereof
BRPI0608178A2 (en) 2005-04-14 2009-11-17 Hoffmann La Roche aminopyrazole derivatives, their manufacture, pharmaceutical composition and use as pharmaceutical agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL91780A (en) * 1988-10-04 1995-08-31 Abbott Lab Renin inhibiting hexanoic acid amide derivatives, process for their preparation and pharmaceutical compositions containing them
IL92011A0 (en) * 1988-10-19 1990-07-12 Abbott Lab Heterocyclic peptide renin inhibitors
CA2010531A1 (en) * 1989-03-06 1990-09-06 Werner Neidhart Amino acid derivatives
AU5407190A (en) * 1989-04-18 1990-11-16 Upjohn Company, The Peptides having novel polar n-terminal groups
DE4001236A1 (en) * 1990-01-18 1991-07-25 Bayer Ag New oligopeptide(s) contg. 2-amino-2-methyl propionic acid residue - are antiviral agents for human or veterinary therapy including treatment of AIDS and ARC

Also Published As

Publication number Publication date
WO1993019059A1 (en) 1993-09-30
KR950700901A (en) 1995-02-20
EP0632808A1 (en) 1995-01-11
FI944428A (en) 1994-09-23
HU9402744D0 (en) 1994-12-28
JPH07501556A (en) 1995-02-16
FI944428A0 (en) 1994-09-23
RU94041225A (en) 1996-07-20
CA2131154A1 (en) 1993-09-30
CZ229594A3 (en) 1995-04-12
NO943540D0 (en) 1994-09-23
SK114094A3 (en) 1995-04-12
BR9306138A (en) 1998-06-23
AU3748393A (en) 1993-10-21

Similar Documents

Publication Publication Date Title
TW200508232A (en) Bicyclic derivatives, their preparation, pharmaceutical compositions containing them and their use in therapy
DE59308619D1 (en) GERMICIDE ACTIVE SUBSTANCE COMBINATIONS
NO943540L (en) Antiviral peptides
ES2126573T3 (en) DERIVATIVE OF PYRAZOLE (1,5-A) PIRIMIDINE AND ANTI-INFLAMMATORY AGENT CONTAINING THIS DERIVATIVE.
MX9706382A (en) Herbicidal benzoyl derivatives.
NO305209B1 (en) N-alkyl-2-substituted ATP analogs, such compounds for the preparation of therapeutics, pharmaceutical preparations containing such compounds, and their use
BG101430A (en) Triazolyl derivatives
MY116917A (en) N-[4-(heteroarylmethyl)phenyl]-heteroarylamines
MY101208A (en) Phenyl-piperazine anti-arrhythmia agents.
ES537182A0 (en) PROCEDURE FOR OBTAINING COMPOUNDS OF 1-ARYL-2- (3- (4-TRIFLUORMETILESTIRIL) -1,2,4-TRIAZOL-1-IL) -1-C 1,2,4, -TRIAZOL-1-IL- METHYL) ETHANOL WITH ANTIFUGAL EFFECT.
PH25859A (en) Composition for treatment of ischemic disorder
DE69106189D1 (en) Substituted benzimidazole and indazole derivatives, processes for their preparation and their use as herbicides.
NZ503822A (en) 2-halo-6-O-substituted erythromycin derivatives, a process for their preparation and pharmaceuticals thereof, useful for treating bacterial infections
BG100815A (en) Insecticidal n-(substituted arylmethyl)-4[bis(substituted phenyl)methyl] piperidines
ES8703406A1 (en) 2-Substituted phenyl-4,5,6,7-tetrahydro-2H-isoindole-1,3-diones, and their production and use.
MXPA04000494A (en) Chemical compounds.
ES482701A1 (en) Derivatives of alpha-azolyl ketones, processes for their preparation and their use as fungicides.
MY118004A (en) Distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents
JPS57169473A (en) Novel bactericidal triazole derivative
HUP9903526A2 (en) Pyrimidine derivatives and pharmaceutical compositions containing the same
FR2334676A1 (en) Fungicidal triazole substd. ethers - with broad activity and low phytotoxicity
ES463162A1 (en) 4,5-Dichloro-imidazole derivatives and their use as plant protection agents
ES481526A1 (en) 1,2,4-Triazol derivatives, a process for their preparation, their use as insecticides and plant growth regulants, and insecticides containing these derivatives.
GB1108288A (en) Improvements in or relating to pyrimidine compounds
MY131321A (en) "antiviral peptides"